ArticleBlood cancer journal2019

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Yuan Xiao Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.